Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study

Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD), Cristina Bezzio, Simone Saibeni, Angela Variola, Mariangela Allocca, Alessandro Massari, Viviana Gerardi, Valentina Casini, Chiara Ricci, Fabiana Zingone, Arnaldo Amato, Flavio Caprioli, Marco Vincenzo Lenti, Chiara Viganò, Marta Ascolani, Fabrizio Bossa, Fabiana Castiglione, Claudio Cortelezzi, Laurino Grossi, Monica MillaDaniela Morganti, Luca Pastorelli, Davide Giuseppe Ribaldone, Alessandro Sartini, Alessandra Soriano, Gianpiero Manes, Silvio Danese, Massimo Fantini, Alessandro Armuzzi, Marco Daperno, Gionata Fiorino

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: COVID-19 has rapidly become a major health emergency worldwide. Patients with IBD are at increased risk of infection, especially when they have active disease and are taking immunosuppressive therapy. The characteristics and outcomes of COVID-19 in patients with IBD remain unclear. Design: This Italian prospective observational cohort study enrolled consecutive patients with an established IBD diagnosis and confirmed COVID-19. Data regarding age, sex, IBD (type, treatments and clinical activity), other comorbidities (Charlson Comorbidity Index (CCI)), signs and symptoms of COVID-19 and therapies were compared with COVID-19 outcomes (pneumonia, hospitalisation, respiratory therapy and death). Results: Between 11 and 29 March 2020, 79 patients with IBD with COVID-19 were enrolled at 24 IBD referral units. Thirty-six patients had COVID-19-related pneumonia (46%), 22 (28%) were hospitalised, 7 (9%) required non-mechanical ventilation, 9 (11%) required continuous positive airway pressure therapy, 2 (3%) had endotracheal intubation and 6 (8%) died. Four patients (6%) were diagnosed with COVID-19 while they were being hospitalised for a severe flare of IBD. Age over 65 years (p=0.03), UC diagnosis (p=0.03), IBD activity (p=0.003) and a CCI score >1 (p=0.04) were significantly associated with COVID-19 pneumonia, whereas concomitant IBD treatments were not. Age over 65 years (p=0.002), active IBD (p=0.02) and higher CCI score were significantly associated with COVID-19-related death. Conclusions: Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not. Preventing acute IBD flares may avoid fatal COVID-19 in patients with IBD. Further research is needed.

Original languageEnglish
Pages (from-to)1213-1217
JournalGut
Volume69
Issue number7
DOIs
Publication statusPublished - 2020

Keywords

  • epidemiology
  • IBD

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study'. Together they form a unique fingerprint.

Cite this